Dr. Wilky on Pembrolizumab Plus Axitinib in Sarcoma

Video

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.

This study is designed to carry immunotherapy one step further, Wilky explains. Although immunotherapy has been found to have some dramatic responses in the field, it does not work for all patients. One of the reasons for the lack of efficacy, she adds, may be due to challenges getting the immune cells into the tumor.

Researchers have shown that the VEGF protein, which most people believe as being responsible for forming new blood vessels to feed tumors, also has direct effects on shutting down the immune system in tumors. Therefore, the concept of the phase II trial, she adds, is to use a VEGF blocker to prime the tumor microenvironment and get immune cells into the tumor. Then, the checkpoint inhibitor pembrolizumab can be used to turn them on.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD